title: A potential role for insulin resistance in experimental pulmonary hypertension.
abstract: Patients with pulmonary arterial hypertension have increased prevalence of insulin resistance. We aimed to determine whether metabolic defects are associated with bone morphogenic protein receptor type 2 (Bmpr2) mutations in mice, and whether these may contribute to pulmonary vascular disease development. Metabolic phenotyping was performed on transgenic mice with inducible expression of Bmpr2 mutation, R899X. Phenotypic penetrance in Bmpr2(R899X) was assessed in a high-fat diet model of insulin resistance. Alterations in glucocorticoid responses were assessed in murine pulmonary microvascular endothelial cells and Bmpr2(R899X) mice treated with dexamethasone. Compared to controls, Bmpr2(R899X) mice showed increased weight gain and demonstrated insulin resistance as assessed by the homeostatic model assessment insulin resistance (1.0 ± 0.4 versus 2.2 ± 1.8) and by fat accumulation in skeletal muscle and decreased oxygen consumption. Bmpr2(R899X) mice fed a high-fat diet had strong increases in pulmonary hypertension penetrance (seven out of 11 versus three out of 11). In cell culture and in vivo experiments, Bmpr2 mutation resulted in a combination of constitutive glucocorticoid receptor activation and insensitivity. Insulin resistance is present as an early feature of Bmpr2 mutation in mice. Exacerbated insulin resistance through high-fat diet worsened pulmonary phenotype, implying a possible causal role in disease. Impaired glucocorticoid responses may contribute to metabolic defects.
authors.affiliation: Pulmonary and Critical Care Medicine T1218 MCN, Vanderbilt University School of Medicine, Nashville, TN, USA. j.west@vanderbilt.edu
authors.forename: James
authors.initials: J
authors.lastname: West
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Niswender
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Johnson
authors.forename: Meredith E
authors.initials: ME
authors.lastname: Pugh
authors.forename: Linda
authors.initials: L
authors.lastname: Gleaves
authors.forename: Joshua P
authors.initials: JP
authors.lastname: Fessel
authors.forename: Anna R
authors.initials: AR
authors.lastname: Hemnes
mesh_terms: D000818:Animals; D001823:Body Composition; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000235:genetics*; D002460:Cell Line; D003907:Dexamethasone / Q000494:pharmacology; D059305:Diet, High-Fat; D004195:Disease Models, Animal; D004734:Energy Metabolism; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000378:metabolism; D007333:Insulin Resistance; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009154:Mutation; D010641:Phenotype; D021381:Protein Transport; D051381:Rats; D011965:Receptors, Glucocorticoid / Q000378:metabolism
chemical_list: D011965:Receptors, Glucocorticoid; D003907:Dexamethasone; C498219:Bmpr2 protein, mouse; D052006:Bone Morphogenetic Protein Receptors, Type II